Related by context. All words. (Click for frequent words.) 71 INCB# [001] 70 Phase 2a trial 69 ISIS # 69 HGS ETR1 69 MGCD# [001] 68 IDX# 68 PS# [001] 68 sapacitabine 67 Phase 1b 67 ganetespib 67 forodesine 67 Phase Ib 66 BCX# 66 PRTX 66 preclinical studies 66 R#/MEM # 66 multiple ascending dose 66 ANAVEX #-# [003] 66 Panzem R 65 INCB# [002] 65 HCV protease inhibitor 65 Phase 2a 65 PXD# 65 voreloxin 65 orally bioavailable 65 oral prodrug 65 Phase 2a clinical 65 perifosine 65 MEK inhibitor 65 HspE7 65 alvespimycin 65 AP# [003] 65 CR# vcMMAE 65 PEG Interferon lambda 65 GRN#L 64 CEQ# 64 Zerenex 64 DAVANAT R 64 Chemophase 64 ApoB SNALP 64 Traficet EN 64 CBLB# 64 CA4P 64 PEG SN# 64 bafetinib 64 thymalfasin 64 HCV protease 64 nitazoxanide 64 PLK1 SNALP 64 OncoVEX GM CSF 64 Perifosine 64 Sym# 64 Azedra 64 pharmacokinetic profile 64 PRX # 64 Phase 2b clinical 64 BAY #-# 64 XL# [003] 64 CORT # 64 ANA# 64 glufosfamide 64 Amigal 64 OXi# 64 MEK inhibitor RDEA# 64 huC# DM4 64 #ME# 63 Azixa 63 investigational drug 63 NGX# 63 pharmacodynamic 63 Archexin 63 refractory gout 63 tanespimycin 63 IMGN# 63 antiviral activity 63 Dapagliflozin 63 Triolex 63 investigational compound 63 tesetaxel 63 ADX# 63 IMA# 63 CK # 63 ALN TTR# 63 ZYBRESTAT 63 Serdaxin 63 phase IIa clinical 63 PCK# 63 obatoclax 63 Marqibo 63 Carfilzomib 63 CoFactor 63 Phase IIa 63 elacytarabine 63 Phase IIa trial 63 MDV# 63 pharmacokinetic PK 63 pomalidomide 63 RG# [001] 63 AEZS 63 ALN VSP 63 LY# [003] 62 HGS ETR2 62 Phase 1b trial 62 Valortim 62 dose cohorts 62 CYT# 62 torezolid phosphate 62 TREANDA 62 phase IIb clinical 62 ALN PCS 62 teduglutide 62 pralatrexate 62 adecatumumab 62 PRT# 62 PDE4 inhibitor 62 SCH # 62 TG# [003] 62 Phase Ib study 62 rNAPc2 62 registrational trial 62 tolerability profile 62 Bezielle 62 MOR# 62 Allovectin 7 R 62 Alpharadin 62 PSN# [002] 62 systemically administered 62 Cloretazine R VNP#M 62 Phase III clinical 62 RGB # 62 metaglidasen 62 ALN RSV# 62 Phase 2b trial 62 pivotal Phase III 62 immunomodulatory 62 generation NNRTI 62 Symadex 62 LymphoStat B 62 custirsen 62 pharmacokinetic 62 TRO# 62 tolerability 62 Phase IIa clinical 62 Tyrima 62 Golimumab 62 carfilzomib 62 favorable pharmacokinetic profile 62 anti leukemic 61 hematological malignancies 61 BiTE antibody 61 preclinical 61 AVN# [001] 61 TMC# [002] 61 SRT# [003] 61 antitumor activity 61 deforolimus 61 ELND# 61 pharmacokinetic properties 61 PMX # 61 polymerase inhibitors 61 Locteron 61 ASONEP 61 TELCYTA 61 GFT# 61 Voreloxin 61 elotuzumab 61 orally administered 61 picoplatin 61 kinase inhibitor 61 CCX# 61 HQK 61 oral dosing 61 AEG# 61 Tezampanel 61 Phase 2b 61 investigational humanized monoclonal antibody 61 oral bioavailability 61 tezampanel 61 TRIOLEX 61 seliciclib 61 Phenoptin 61 dose escalation study 61 virus HCV protease inhibitor 61 oral ridaforolimus 61 Genasense ® oblimersen 61 Androxal 61 talactoferrin 61 small molecule defensin 61 anticancer compound 61 MGCD# [002] 61 HER2 positive metastatic breast 61 Tesetaxel 61 elvitegravir 61 EndoTAG TM -1 61 telbivudine 61 eniluracil 61 Exherin TM 61 transcriptase inhibitor NNRTI 61 celgosivir 61 pertuzumab 61 mertansine 61 PNP inhibitor 61 sodium glucose cotransporter 61 PEG PAL 61 humanized anti 61 axitinib 61 Phase IIb 61 lesinurad 61 MEK inhibitors 61 anticancer agent 61 Phase 1b clinical 61 bevirimat 61 sodium Injection 60 Blinatumomab 60 imetelstat 60 laquinimod 60 PDX pralatrexate 60 orally administered inhibitor 60 Ophena TM 60 anti amnesic 60 NKTR 60 eltrombopag 60 Picoplatin 60 histone deacetylase HDAC inhibitor 60 atacicept 60 ALN TTR 60 Tarvacin TM 60 Phase IIb clinical 60 CRx 60 uric acid lowering 60 vidofludimus 60 ProLindac 60 Phase Ib clinical 60 HCD# [002] 60 investigational oral 60 veltuzumab 60 XmAb# 60 Interferon alpha 60 ENMD # 60 Alocrest 60 mapatumumab 60 CYC# 60 Laquinimod 60 posaconazole 60 enzastaurin 60 JAK inhibitor 60 preclinically 60 Omacetaxine 60 Imprime PGG 60 IRX 2 60 Menerba 60 mGluR5 negative 60 lintuzumab 60 Fx #A 60 Panzem R NCD 60 2 methoxyestradiol 60 Solazed TM 60 CIMZIA TM 60 docetaxel Taxotere R 60 PD LID 60 JAK inhibitors 60 TMC# [001] 60 Phase IIb trials 60 Debio 60 immunomodulator 60 Phase 1a 60 JAK1 60 alagebrium 60 cetuximab Erbitux ® 60 generation Hsp# inhibitor 60 SAR# [004] 60 vascular disrupting agent 60 ELACYT 60 GLPG# 60 OMP #M# 60 mGluR5 NAM 60 sorafenib tablets 60 Bortezomib 60 targeted radiotherapeutic 60 DAVANAT ® 60 MLN# 60 leading oral taxane 60 evaluating tivozanib 60 ZADAXIN 60 GALNS 60 selective androgen receptor modulator 60 CINOD 60 davunetide 60 vilazodone 60 pharmacodynamic PD 60 QLT# 60 pharmacodynamic properties 59 Cethromycin 59 AZILECT R 59 lomitapide 59 investigational pan BCR 59 sorafenib Nexavar 59 KRN# 59 DB# [003] 59 oritavancin 59 elagolix 59 HuLuc# 59 CCR5 antagonist 59 registrational 59 proteasome inhibitor 59 REMUNE R 59 TPI ASM8 59 CTCE 59 Cloretazine 59 polymerase inhibitor 59 Phase 1a clinical 59 Valortim R 59 Amrubicin 59 IMP# 59 PROSTVAC TM 59 GATTEX 59 FTY# 59 immunogenicity 59 iSONEP 59 Nanobody 59 TELINTRA 59 ocular formulation 59 MAP# 59 administered subcutaneously 59 Protexia ® 59 ofatumumab 59 PI3K/Akt pathway inhibitor 59 Locteron ® 59 vosaroxin 59 epothilone 59 Lenocta 59 Cyclooxygenase Inhibiting Nitric Oxide 59 Phase Ib II 59 Vidofludimus 59 Aurora kinase 59 raltegravir 59 Excellarate 59 IMC A# 59 tamibarotene 59 PSMA ADC 59 biodistribution 59 TriRima 59 Androxal TM 59 TACI Ig 59 Tamibarotene 59 Valortim ® 59 HuMax EGFr 59 Phase IIb trial 59 MEK Inhibitor 59 ISTODAX 59 nucleoside analog 59 fosbretabulin 59 integrase inhibitor 59 Phase III clinical trials 59 pivotal Phase 59 Phase Ia 59 Oral NKTR 59 Naproxcinod 59 diabetic neuropathic pain 59 otelixizumab 59 ENMD 59 dose escalation trial 59 NVA# 59 metastatic castration resistant 59 xenograft models 59 AMR# 59 GLP toxicology studies 59 Xanafide 59 liposomal formulation 59 Genz # 59 nucleotide analog 59 Phase #/#a trial 59 RLY# 59 GLYX 59 erlotinib Tarceva ® 59 Phase 2b study 59 TKM ApoB 59 VA# [002] 59 Androxal ® 59 Pegasys ® 59 Prodarsan ® 59 MAXY G# 59 TYZEKA 59 next generation URAT1 59 albinterferon alfa 2b 59 BAL# [001] 59 depsipeptide 59 lintuzumab SGN 59 docetaxel chemotherapy 59 ascending dose 59 NXL# 59 dosing cohort 59 generation URAT1 inhibitor 59 CORLUX 59 ATL# [001] 59 NEUGENE 59 AEGR 59 CUDC 59 anti EGFR antibody 59 Nexavar ® 59 sunitinib malate 59 bavituximab 59 NEUMUNE 59 KNS # 59 mitogen activated ERK kinase 59 pan HDAC inhibitor 59 ARRY 59 MAGE A3 ASCI 59 Trastuzumab 58 calcitonin 58 Aflibercept 58 rindopepimut 58 NU# [001] 58 solithromycin 58 orally dosed 58 Dasatinib 58 AEOL # 58 lorvotuzumab mertansine 58 Belinostat 58 oral antiviral 58 Ozarelix 58 CTAP# Capsules 58 TOCOSOL Paclitaxel 58 Phase IIa trials 58 subcutaneous formulation 58 Synavive 58 Apoptone 58 HGS# 58 Serdaxin ® 58 HuMax CD4 58 placebo controlled Phase 58 trastuzumab DM1 T DM1 58 RhuDex ® 58 demonstrated antitumor activity 58 Mipomersen 58 Elesclomol 58 sulodexide 58 CIMZIA ™ 58 dosing regimens 58 immune modulatory 58 protease inhibitor 58 dasatinib 58 preclinical efficacy 58 Guanilib 58 dose cohort 58 eprotirome 58 TG# [001] 58 nab paclitaxel 58 ONCONASE 58 Pimavanserin 58 PKC# 58 ZYBRESTAT fosbretabulin 58 hormone refractory prostate cancer 58 APD# 58 XL# XL# 58 APF# 58 generation antisense 58 AzaSite Plus 58 phase IIb 58 ongoing Phase 1b 58 phase IIa 58 BioVant 58 Bavituximab 58 HRPC 58 belinostat 58 antitumor 58 elesclomol 58 APOPTONE 58 Cinryze ™ 58 indibulin 58 Omacetaxine mepesuccinate 58 Preclinical studies 58 PREZISTA r 58 Alzhemed TM 58 CCR9 antagonist 58 darinaparsin 58 lenalidomide Revlimid R 58 Tarvacin 58 MT# MEDI 58 PRX# 58 pharmacokinetic PK study 58 Bendavia 58 nucleoside reverse transcriptase inhibitor 58 AQ4N 58 viral kinetics 58 Pivotal Phase III 58 Darinaparsin 58 C1 INH 58 nonclinical studies 58 multi kinase inhibitor 58 relapsed refractory multiple myeloma 58 HE# [002] 58 NNRTI 58 compound INCB# 58 cilengitide 58 Ostarine 58 radezolid 58 non nucleoside inhibitor 58 GAMMAGARD 58 LibiGel ® 58 T DM1 58 novel VDA molecule 58 novel anticancer 58 DermaVir Patch 58 interferon alfa 58 tivozanib 58 rBChE 58 anti TNF alpha 58 phase 2a 58 velafermin belinostat 58 Protexia R 58 YONDELIS 58 Capesaris 58 tezampanel NGX# 58 Radezolid 58 immunotherapeutic agent 58 allosteric modulator 58 mipomersen 58 velafermin 58 AZD# 58 non nucleoside HCV 58 OHR/AVR# 58 Phase Ib clinical trials 58 teriflunomide 58 Posiphen 58 trodusquemine 58 panitumumab 58 daclizumab 58 tgAAC# 58 Hsp# inhibitor 58 TBC# 58 INGN 58 Abiraterone acetate 58 PF # [001] 58 Taxotere ® 58 ISENTRESS 58 Reverset 58 histone deacetylase inhibitor 58 oral FTY# 58 fluvastatin 58 afatinib 58 #D#C# 58 DXL# 58 temsirolimus 58 Indibulin 58 HCV polymerase inhibitors 58 Atiprimod 58 IMC #B 58 AMD# [002] 58 heavily pretreated 58 Protectan CBLB# 58 retapamulin 58 Restanza 58 pitavastatin 58 androgen independent 58 LT NS# 58 Fibrillex TM 58 Protease Inhibitor 57 humanized monoclonal antibody 57 DR Cysteamine 57 Virulizin ® 57 pramlintide 57 ADVEXIN 57 angiogenesis inhibitor 57 protein kinase inhibitor 57 huN# DM1 57 pharmacokinetics 57 SILENOR TM 57 arimoclomol 57 ZADAXIN ® 57 Glufosfamide 57 randomized Phase 57 CD# CEA 57 eculizumab 57 dasatinib Sprycel ® 57 cutaneous T cell 57 cannabinor 57 ostarine 57 Seliciclib 57 PROVENGE sipuleucel T 57 ZD# [001] 57 bortezomib 57 xanthine oxidase inhibitor 57 immunotherapeutic 57 BRIM2 57 febuxostat 57 decitabine 57 riociguat 57 paclitaxel Taxol ® 57 anticancer activity 57 pharmacokinetics pharmacodynamics 57 immunomodulating 57 MultiStem 57 oral proteasome inhibitor 57 Pazopanib 57 CBLC# 57 Cloretazine ® 57 PEGPH# 57 ORMD 57 Personalized Immunotherapy 57 vandetanib 57 EOquin TM 57 LEP ETU 57 MOZOBIL 57 FGFR 57 receptor tyrosine kinase inhibitor 57 Genasense R oblimersen 57 telaprevir dosed 57 Nanobody ® 57 Arimoclomol 57 entinostat 57 hematological cancers 57 vorinostat 57 Panzem 57 inhibitor RG# 57 BENLYSTA ® 57 relapsed multiple myeloma 57 ADXS# 57 SinuNase TM 57 rFIXFc 57 ZK EPO 57 viral kinetic 57 Azedra TM 57 INT# [002] 57 TYKERB 57 DAVANAT 57 XL# XL# XL# XL# 57 NOX E# 57 castrate resistant prostate cancer 57 EcoNail 57 alvimopan 57 Asentar 57 FOLOTYN ® 57 CD# antibody [001] 57 valopicitabine 57 Anturol ® 57 ritonavir boosted 57 cell lymphoma CTCL 57 CDK inhibitor 57 ABL inhibitor 57 Stedivaze 57 IAP inhibitors 57 Exenatide 57 Palifosfamide 57 maturation inhibitor 57 HIV RDEA# 57 selective kinase inhibitor 57 Zemiva ™ 57 neuroprotective properties 57 ruxolitinib 57 Randomized Phase 57 EOquin 57 mRCC 57 Aplidin 57 chlorambucil 57 bevacizumab Avastin ® 57 Clevudine 57 XL# anticancer compounds 57 Curaxin CBLC# 57 Aurexis 57 APTIVUS r 57 vivo efficacy 57 Phase #b/#a clinical 57 Vilazodone 57 LY# [002] 57 Elotuzumab 57 JANUVIA 57 EFAPROXYN 57 ATL/TV# 57 targeting CD# 57 XL# XL# XL# 57 SPC# [001] 57 CG# [003] 57 telaprevir VX 57 Talabostat 57 CTA# Injection 57 nucleoside analogues 57 pharmacodynamic profile 57 NP2 Enkephalin 57 ascending doses 57 Allovectin 7 ® 57 blinatumomab 57 ITMN 57 therapeutic monoclonal antibody 57 APTIVUS 57 allosteric modulator NAM 57 milatuzumab 57 RSD# oral 57 hGH CTP 57 maximally tolerated dose 57 gemcitabine 57 oral rivaroxaban 57 Copegus ribavirin 57 AVE# 57 MB# [004] 57 RNAi therapeutic 57 phase Ib 57 rHuPH# 57 PHX# 57 Pivotal Phase 57 PTH analogue 57 nucleoside 57 polysaccharide polymer 57 bendamustine 57 investigational hepatitis C 57 pharmacodynamics 57 generation PNP inhibitor 57 HDAC Inhibitor 57 vinca alkaloid 57 OncoVEX 57 Phase 2b Clinical Trial 57 Phase 2b clinical trials 57 cutaneous T 57 amrubicin 57 Hsp# Inhibitor 57 CRLX# 57 IMiDs R 57 investigational monoclonal antibody 57 GMX# 57 SparVax TM 57 clinical pharmacology studies 57 pegylated interferon alpha 57 MYDICAR ® 57 palifosfamide 57 XYOTAX TM 57 bortezomib Velcade 57 dose limiting toxicities 57 Aclidinium 57 abiraterone acetate 57 diabetic nephropathy 57 JVRS 57 Proxinium TM 57 PBT2 57 NS5A 57 Phase #b/#a trial 57 proteasome inhibitors 57 ozarelix 57 dextofisopam 57 systemic RNAi therapeutic 57 Vicriviroc 57 Phase IIIb clinical 57 Telbivudine 57 CGEN # 57 delafloxacin 57 potent antiviral 57 DACH platinum 57 relapsing remitting multiple sclerosis 57 dimebon 57 neratinib 57 Nasulin 57 lead Aganocide compound 57 MyVax R 57 IND enabling 57 Virulizin R 57 dose escalation Phase 56 S/GSK# 56 MBP# [001] 56 pegylated interferons 56 cMET 56 taxane 56 Boceprevir 56 Anturol 56 ANG# 56 ProSavin 56 castration resistant prostate cancer 56 Tanespimycin 56 taxanes 56 RNAi therapeutic targeting 56 romidepsin 56 single ascending dose 56 FOLOTYN 56 Azedra ™ 56 Pralatrexate 56 Phase IIb Trial 56 R roscovitine 56 ICA # 56 canakinumab 56 Phase #b/#a 56 ixabepilone 56 Ocrelizumab 56 ACTEMRA 56 DDP# 56 HDAC inhibitor 56 Amplimexon 56 Epothilones 56 pharmacokinetic studies 56 Rasagiline 56 CYT# potent vascular disrupting 56 pegylated interferon alfa 2a 56 dacetuzumab SGN 56 Riquent 56 somatostatin analogue 56 Gemzar ® 56 INCB# [003] 56 Enzastaurin 56 Hsp# inhibitors 56 azacitidine 56 crizotinib PF # 56 Daclizumab 56 Phase III Clinical Trial 56 Phase IIB 56 IIa trial 56 confirmatory Phase III 56 Plicera 56 disease modifying 56 ORENCIA ® 56 Trofex 56 renin inhibitor 56 Rebif ® 56 VEGF Trap 56 PROMACTA 56 HGS ETR1 mapatumumab 56 MAXY alpha 56 tolerability profiles 56 Chrysalin 56 lupus nephritis 56 Targretin 56 urate lowering 56 docetaxel 56 SERMs 56 potent inhibitor 56 Elagolix 56 Fludara 56 pegfilgrastim 56 ANAVEX #-# [001] 56 davunetide intranasal AL 56 CCR5 mAb 56 Bicifadine 56 Albuferon 56 nanoviricides 56 LymphoStat B belimumab 56 PEGylated 56 oral nucleoside analogue 56 tesmilifene 56 IL# PE#QQR 56 Forodesine HCl 56 L MTP PE 56 antisense drug 56 immunosuppressive 56 biologic therapy 56 Quinamed 56 insulin sensitizers 56 Q#IR 56 LymphoStat B TM 56 Sapacitabine 56 sorafenib Nexavar ® 56 vicriviroc 56 safety tolerability pharmacokinetics 56 Phase 2a clinical trials 56 vascular disrupting agents 56 mGluR2 NAM 56 Onalta 56 H#N# VLP vaccine 56 brostallicin 56 chemotherapy induced neutropenia 56 hematologic malignancies 56 BENLYSTA 56 metastatic castrate resistant 56 Sphingomab 56 ELND-#/AZD-# 56 Vaxfectin 56 Factor VIIa 56 virus HCV infection 56 LEVADEX 56 Darusentan 56 Xcytrin R 56 oral anticancer 56 generation MEK inhibitor 56 prodrug 56 ANYARA 56 Cetrorelix 56 aflibercept 56 tafamidis 56 lymphoma CTCL 56 drug pipeline TAFA# 56 brentuximab vedotin SGN 56 Zoraxel TM 56 RiVax 56 selective inhibition 56 Hyphanox 56 Tarceva TM 56 Adalimumab 56 PrevOnco ™ 56 Pathway Inhibitor 56 SUCCEED trial 56 mcg dose 56 Aplidin R 56 perifosine KRX 56 antiviral efficacy 56 satraplatin 56 Onconase 56 Phase 2a Clinical Trial 56 chronic hepatitis C. 56 JAK2 inhibitor 56 Phase 2b Trial 56 brivaracetam 56 plus Copegus R 56 pharmacokinetics PK 56 forodesine hydrochloride 56 Genasense oblimersen sodium Injection 56 Solazed 56 Shigamabs R 56 imatinib Gleevec ® 56 CD# monoclonal antibody 56 Anthim 56 bardoxolone methyl 56 masitinib 56 antitumor effects 56 BZL# 56 liprotamase 56 Romidepsin 56 docetaxel Taxotere ® 56 subcutaneously administered 56 anticancer agents 56 immunogenic 56 Genasense ® 56 Plenaxis TM 56 VQD 56 AKT inhibitor 56 VAPRISOL 56 BiovaxID 56 Onalta ™ 56 indacaterol 56 uricase 56 Annamycin 56 radiation sensitizer 56 forodesine HCl 56 YONDELIS R 56 Initiate Phase 56 Reolysin 56 hormone LHRH antagonist 56 Gemcitabine 56 TLK# 56 Pradefovir 56 Civacir 56 OPAXIO 56 highly selective inhibitor 56 Icatibant 56 preclinical models 56 rilonacept 56 CB2 selective receptor agonist 56 chemotherapeutic agent 56 darapladib 56 MAA submission 56 Ofatumumab 56 inhaled formulation 56 bevacizumab Avastin 56 Cotara 56 PREOS 56 IND submission 56 dacetuzumab 56 nucleoside reverse transcriptase inhibitors 56 microplasmin 56 MGd 56 6R BH4 56 talabostat 56 Tasimelteon 56 PEGylated interferon beta 1a 56 Linaclotide 56 alkylating agent 56 Lixisenatide 56 Irinotecan 56 anticancer 56 farletuzumab 56 pharmacokinetic PK profile 56 HCV genotypes 56 GM CSF 56 visilizumab 56 ataluren 56 TH# [003] 56 erythropoietic 56 initiate Phase 56 dyskinesia PD LID 55 Antiviral Activity 55 confirmatory Phase 3 55 PLX# 55 panobinostat 55 BENLYSTA TM 55 Phase III 55 ILUVIEN ® 55 Microplasmin 55 immune modulating 55 Marqibo TM 55 metastatic hormone refractory 55 XP# XP# 55 HCV protease inhibitors 55 nucleotide analogue 55 alfa 2a 55 safety tolerability pharmacokinetic 55 metastatic renal cell carcinoma 55 factor G CSF 55 anti angiogenic 55 Pharmacokinetics PK 55 trastuzumab Herceptin R 55 delivered RNAi therapeutic 55 DU #b 55 IMPDH inhibitor 55 phase IIb study 55 receptor inhibitor